Positive study results typically lead to increased investor confidence, potentially driving up the stock price in the short term. Given the significance of these results for Silo Pharma's product pipeline, particularly in the high-need area of mental health treatments, the impact on SILO's stock could be notably positive. The announcement directly pertains to the company's core business and represents a significant milestone in the development of its key product, SPC-15.